共 50 条
- [21] Circularly Permuted TRAIL (CPT) combined with Thalidomide for the Treatment of Relapsed or Refractory Multiple Myeloma: An Open-Label, Multicenter Phase II Clinical Trial.BLOOD, 2012, 120 (21)Chen, WenmingHou, JianZhao, YaozhongQiu, LuguiKe, XiaoyanWang, ZhaoLeng, YunJing, HongmeiXi, HaoZheng, XiangjunWang, FuxuZhu, BingYang, Shifang
- [22] Combined bendamustine, prednisolone and thalidomide for refractory or relapsed multiple myeloma after autologous stem-cell transplantation or conventional chemotherapy:: results of a Phase I clinical trialBRITISH JOURNAL OF HAEMATOLOGY, 2008, 143 (02) : 191 - 200Poenisch, WolframRozanski, MartaGoldschmidt, HartmutHoffmann, Franz AlbertBoldt, ThomasSchwarzer, AndreasRitter, UteRohrberg, RobertSchwalbe, ElkeUhlig, JensZehrfeld, ThomasSchirmer, VeronikaHaas, AntjeKreibich, UteNiederwieser, Dietger
- [23] Phase I Study of the Combination of Carfilzomib and Panobinostat for Patients with Relapsed and Refractory Myeloma: A Multiple Myeloma Research Consortium (MMRC) Clinical TrialBLOOD, 2014, 124 (21)Kaufman, Jonathan L.Zimmerman, ToddRosenbaum, Cara A.Nooka, Ajay K.Heffner, Leonard T.Harvey, R. DonaldGleason, ChariseLewis, ColleenSharp, CathyBarron, Kenisha W.Lonial, Sagar
- [24] Velcade, Thalidomide, Dexamethasone and Panobinostat (VTD-P) for Patients with Relapsed and Relapsed/Refractory Myeloma: Preliminary Results of the Muk-Six Phase I/IIa TrialBLOOD, 2014, 124 (21)Popat, RakeshBrown, SarahFlanagan, Louise M.Cavenagh, James D.
- [25] Bortezomib in combination with pegylated liposomal doxorubicin and thalidomide is an effective steroid independent salvage regimen for patients with relapsed or refractory multiple myeloma: results of a phase II clinical trialLEUKEMIA & LYMPHOMA, 2009, 50 (07) : 1096 - 1101Chanan-Khan, AsherMiller, Kena C.Musial, LauriePadmanabhan, SwaminathanYu, JihnheeAilawadhi, SikanderSher, TaimurMohr, AliceBernstein, Zale P.Barcos, MauricePatel, MehulIancu, DanLee, KelvinCzuczman, Myron S.
- [26] A Phase II Clinical Trial of the Anti-EGFR Antibody Cetuximab in Patients with Refractory or Relapsed Multiple Myeloma: Final ResultsBLOOD, 2011, 118 (21) : 1696 - 1696von Tresckow, BastianBoell, BorisEichenauer, Dennis A.Peine, DenissaKnop, StefanGoebeler, MarieleChemnitz, Jens M.Hallek, MichaelEngert, AndreasHuebel, Kai
- [27] Phase 1 Clinical Trial of the Novel Structure Proteasome Inhibitor NPI-0052 in Patients with Relapsed and Relapsed/Refractory Multiple Myeloma (MM)BLOOD, 2009, 114 (22) : 179 - 179Richardson, PaulHofmeister, CraigJakubowiak, AndrzejZimmerman, Todd M.Spear, Matthew A.Palladino, Michael A.Longenecker, Angie M.Kelly, Susan L.Neuteboom, SaskiaCropp, Gillian F.Lloyd, G. KennethHannah, Alison L.Anderson, Kenneth C.
- [28] CAMMA 3: A multicenter phase Ib trial evaluating the safety, pharmacokinetics, and activity of subcutaneous cevostamab monotherapy in patients with relapsed or refractory multiple myeloma.JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)Delimpasi, SosanaQuach, HangCavo, MicheleHo, P. JoyLee, CindySantoro, ArmandoSchots, RikVlummens, PhilipYoon, Dok HyunYoon, Sung-SooDos Santos, CedricSamineni, DivyaHuang, JiangengWehrman, KristinPatil, UpenSheikh, SemiraDimopoulos, Meletios A.
- [29] Safety and efficacy of the combination of bortezomib and dexamethasone with the deacetylase inhibitor romidepsin in patients with relapsed and refractory multiple myeloma: preliminary results of a phase I trialBRITISH JOURNAL OF HAEMATOLOGY, 2008, 141 : 33 - 33Prince, H. M.Quach, H.Yuen, K.Keegan, M.Copeman, M.Peinert, S.Bishton, M.Wolf, M.Westerman, D.Ritchie, D.Seymour, J. F.Carney, D.Harrison, S. J.
- [30] Bortezomib, low dose intravenous melphalan and dexamethasone for patients with relapsed multiple myeloma: results of a phase I/II clinical trialBRITISH JOURNAL OF HAEMATOLOGY, 2007, 137 : 60 - 61Popat, R.Williams, C.Cook, M.Craddock, C.Basu, S.Singeri, C.Gurnbleton, T.Foot, N.Oakervee, H.Cavenagh, J.